India's Covaxin Effective Against Delta+ Variant, Claims ICMR Study

According to the study done by the Indian Council of Medical Research (ICMR), India's Covaxin developed by Bharat  Biotech is potent against the Delta Plus (AY.1) variant of the SARS-CoV2 virus. The Delta AY.1 variant was first detected in India in April 2021 but is found to be low. "Our research showed that Covaxin could still neutralize Delta, AY.1 and B.1.617.3 variants," said Dr. Samiran Panda, head of epidemiology and communicable diseases, ICMR.